171 related articles for article (PubMed ID: 34455511)
21. Appendiceal goblet cell carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Randle RW; Griffith KF; Fino NF; Swett KR; Stewart JH; Shen P; Levine EA; Votanopoulos KI
J Surg Res; 2015 Jun; 196(2):229-34. PubMed ID: 25881787
[TBL] [Abstract][Full Text] [Related]
22. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix.
McConnell YJ; Mack LA; Gui X; Carr NJ; Sideris L; Temple WJ; Dubé P; Chandrakumaran K; Moran BJ; Cecil TD
Ann Surg Oncol; 2014 Jun; 21(6):1975-82. PubMed ID: 24398544
[TBL] [Abstract][Full Text] [Related]
23. Defining "Complete Cytoreduction" After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis.
Munoz-Zuluaga CA; King MC; Diaz-Sarmiento VS; Studeman K; Sittig M; MacDonald R; Nieroda C; Zambrano-Vera K; Gushchin V; Sardi A
Ann Surg Oncol; 2020 Dec; 27(13):5026-5036. PubMed ID: 32705513
[TBL] [Abstract][Full Text] [Related]
24. Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Cummins KA; Russell GB; Votanopoulos KI; Shen P; Stewart JH; Levine EA
J Gastrointest Oncol; 2016 Feb; 7(1):3-9. PubMed ID: 26941979
[TBL] [Abstract][Full Text] [Related]
25. Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite Experience.
Solomon D; Bekhor E; Leigh N; Maniar YM; Totin L; Hofstedt M; Aycart SN; Carr J; Ballentine S; Magge DR; Golas BJ; Pai RK; Polydorides AD; Bartlett DL; Labow DM; Choudry HA; Sarpel U
Ann Surg Oncol; 2020 Jan; 27(1):147-153. PubMed ID: 31385130
[TBL] [Abstract][Full Text] [Related]
26. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms.
Erstad DJ; Robinson KA; Beaty K; Rafeeq S; Chiang YJ; Raghav K; Shen JP; Overman MJ; Foo WC; Taggart MW; Mansfield PF; Royal RE; Fournier KF; Scally CP
Langenbecks Arch Surg; 2023 Feb; 408(1):110. PubMed ID: 36853519
[TBL] [Abstract][Full Text] [Related]
28. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
[TBL] [Abstract][Full Text] [Related]
29. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
[TBL] [Abstract][Full Text] [Related]
30. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
31. Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei.
Beane JD; Wilson GC; Sutton JM; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Holtzman MP; Zureikat AJ; Ahrendt SA; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2019 May; 26(5):1429-1436. PubMed ID: 30623341
[TBL] [Abstract][Full Text] [Related]
32. Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
Rao A; Mui J; Barat S; Matar AA; Alzahrani N; Morris DL
Anticancer Res; 2021 Nov; 41(11):5569-5575. PubMed ID: 34732427
[TBL] [Abstract][Full Text] [Related]
33. Predicting Aborted Hyperthermic Intraperitoneal Chemotherapy (AHIPEC) with Preoperative Tumor and Inflammatory Markers in Potentially Resectable Appendiceal Cancer Patients with Peritoneal Carcinomatosis.
Baron E; Milovanov V; Gushchin V; Sittig M; Neiroda C; Sardi A
Ann Surg Oncol; 2020 Jul; 27(7):2548-2556. PubMed ID: 31980984
[TBL] [Abstract][Full Text] [Related]
34. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
[TBL] [Abstract][Full Text] [Related]
35. Managing Recurrent Pseudomyxoma Peritonei in 430 Patients After Complete Cytoreduction and HIPEC: A Dilemma for Patients and Surgeons.
Ahmadi N; Kostadinov D; Sakata S; Ball WR; Gandhi J; Carr NJ; Tzivanakis A; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Ann Surg Oncol; 2021 Nov; 28(12):7809-7820. PubMed ID: 34041626
[TBL] [Abstract][Full Text] [Related]
36. Overall Survival after Systemic Chemotherapy in Patients with High-Grade Appendiceal Cancer Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Nagarajan B; Singh J; Gelli A; Lenin J; Prabhu S; Sundaramurthi S
J Gastrointest Surg; 2022 Dec; 26(12):2628-2629. PubMed ID: 36344797
[No Abstract] [Full Text] [Related]
37. Oncologic Risk Stratification Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Carcinomatosis.
Wagner PL; Austin F; Zenati M; Jaech A; Mavanur A; Ramalingam L; Jones HL; Holtzman MP; Ahrendt SA; Zureikat AH; Pingpank JF; Zeh HJ; Bartlett DL; Choudry HA
Ann Surg Oncol; 2016 May; 23(5):1587-93. PubMed ID: 26744106
[TBL] [Abstract][Full Text] [Related]
38. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
[TBL] [Abstract][Full Text] [Related]
39. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy vs. cytoreductive surgery alone for intrahepatic cholangiocarcinoma with peritoneal metastases: A retrospective cohort study.
Feng F; Gao Q; Wu Y; Liu C; Yu Y; Li B; Chu K; Yi B; Cheng Q; Jiang X
Eur J Surg Oncol; 2021 Sep; 47(9):2363-2368. PubMed ID: 34119376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
